Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOURward: Short Duration Quad Therapy for Hepatitis C
NCT02175966Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daclatasvir, asunaprevir and beclabuvir in hepatitis C (HCV) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Sustained Virologic Response 12, Deaths, Serious Adverse Events, and AEs Leading to Discontinuation up to 17 months and 1 more. Started Jul 2014; status: completed.
02
Drugs
daclatasvirasunaprevirbeclabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02175966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02175966.